BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $195,235,808 | -14.2% | 5,173,180 | +3.6% | 0.02% | -12.5% |
| Q2 2023 | $227,471,102 | +2.9% | 4,992,781 | -8.4% | 0.02% | +4.3% |
| Q1 2023 | $221,017,737 | -33.4% | 5,449,155 | -16.3% | 0.02% | -39.5% |
| Q4 2022 | $332,022,182 | -15.6% | 6,514,071 | -10.8% | 0.04% | -19.1% |
| Q3 2022 | $393,181,000 | -2.7% | 7,300,049 | +16.1% | 0.05% | +2.2% |
| Q2 2022 | $403,982,000 | -16.1% | 6,289,627 | +1.3% | 0.05% | 0.0% |
| Q1 2022 | $481,460,000 | -6.9% | 6,209,167 | +3.1% | 0.05% | -9.8% |
| Q4 2021 | $517,176,000 | +20.1% | 6,024,887 | +12.5% | 0.05% | +13.3% |
| Q3 2021 | $430,589,000 | +19.9% | 5,353,589 | +20.0% | 0.04% | +21.6% |
| Q2 2021 | $359,130,000 | -9.6% | 4,461,248 | -5.3% | 0.04% | -17.8% |
| Q1 2021 | $397,454,000 | +47.8% | 4,712,527 | +40.7% | 0.04% | +28.6% |
| Q4 2020 | $268,833,000 | -7.7% | 3,350,362 | -7.5% | 0.04% | -12.5% |
| Q3 2020 | $291,410,000 | +0.8% | 3,623,603 | +7.9% | 0.04% | -9.1% |
| Q2 2020 | $289,067,000 | +2.6% | 3,357,342 | -3.2% | 0.04% | -13.7% |
| Q1 2020 | $281,615,000 | -15.9% | 3,468,606 | -13.4% | 0.05% | +6.2% |
| Q4 2019 | $334,829,000 | -62.1% | 4,004,172 | -60.3% | 0.05% | -63.4% |
| Q3 2019 | $882,422,000 | +13.1% | 10,088,292 | +5.9% | 0.13% | +12.0% |
| Q2 2019 | $780,526,000 | +30.4% | 9,530,214 | +29.4% | 0.12% | +25.8% |
| Q1 2019 | $598,762,000 | +106.7% | 7,363,940 | +67.3% | 0.09% | +82.4% |
| Q4 2018 | $289,694,000 | -12.7% | 4,401,295 | +2.3% | 0.05% | -1.9% |
| Q3 2018 | $331,724,000 | +1.6% | 4,303,067 | -2.7% | 0.05% | -3.7% |
| Q2 2018 | $326,398,000 | +14.6% | 4,420,344 | +1.0% | 0.05% | +10.2% |
| Q1 2018 | $284,764,000 | -0.9% | 4,378,292 | -1.5% | 0.05% | +2.1% |
| Q4 2017 | $287,328,000 | -10.9% | 4,445,058 | -13.5% | 0.05% | -5.9% |
| Q3 2017 | $322,532,000 | +17.0% | 5,139,957 | +12.9% | 0.05% | -7.3% |
| Q2 2017 | $275,615,000 | +23.6% | 4,552,627 | +5.8% | 0.06% | +25.0% |
| Q1 2017 | $223,070,000 | +19.9% | 4,301,369 | +2.5% | 0.04% | +7.3% |
| Q4 2016 | $186,036,000 | -2.1% | 4,195,671 | +5.1% | 0.04% | -2.4% |
| Q3 2016 | $190,017,000 | -46.6% | 3,991,941 | -49.3% | 0.04% | -49.4% |
| Q2 2016 | $356,062,000 | -20.8% | 7,873,972 | -28.0% | 0.08% | -24.5% |
| Q1 2016 | $449,538,000 | +112.5% | 10,942,967 | +97.3% | 0.11% | +124.5% |
| Q4 2015 | $211,576,000 | +16.4% | 5,545,931 | +0.2% | 0.05% | +8.9% |
| Q3 2015 | $181,840,000 | -55.4% | 5,535,461 | -5.1% | 0.04% | -65.9% |
| Q2 2015 | $408,084,000 | +0.8% | 5,835,620 | -1.2% | 0.13% | -2.9% |
| Q1 2015 | $404,675,000 | -10.4% | 5,907,666 | -4.1% | 0.14% | -16.0% |
| Q4 2014 | $451,700,000 | -42.5% | 6,163,176 | -43.7% | 0.16% | -36.5% |
| Q3 2014 | $786,194,000 | -4.5% | 10,954,342 | -3.8% | 0.26% | -3.4% |
| Q2 2014 | $823,250,000 | +98.4% | 11,386,590 | +101.9% | 0.26% | +71.4% |
| Q1 2014 | $414,999,000 | -6.8% | 5,640,095 | -11.9% | 0.15% | -3.8% |
| Q4 2013 | $445,505,000 | -7.4% | 6,405,554 | -12.5% | 0.16% | -16.7% |
| Q3 2013 | $480,961,000 | -34.5% | 7,321,704 | -31.0% | 0.19% | -37.9% |
| Q2 2013 | $734,668,000 | – | 10,605,881 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |